Author: Daniel A. Saez, MSc, Manager of LungMATCH Navigation Program Despite 2021 being another challenging year, we saw treatment options for lung cancer increase by leaps and bounds. In 2021 the treatment landscape for lung cancer evolved to provide breakthrough treatment [...]
Despite 2021 being another challenging year, we saw treatment options for lung cancer increase by leaps and bounds. In 2021 the treatment landscape for lung cancer evolved to provide breakthrough treatment options targeting mutations that were previously unavailable for [...]
On September 15th, 2021, the Food and Drug Administration (FDA) approved Exkivity (mobocertinib) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in EGFR called exon 20 insertion. The FDA based their approval on the results [...]
On May 28, 2021 the United States Food and Drug Administration (FDA) approved Lumakras (sotorasib) for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having the G12C change in KRAS. The FDA based their approval [...]
On August 26th, 2020, the Food and Drug Administration (FDA) approved the FoundationOne Liquid CDx for comprehensive liquid biopsy biomarker testing for patients with any solid tumor. The FDA based their approval on analysis from multiple clinical validation studies [...]
On August 7th, 2020, the Food and Drug Administration (FDA) approved the Guardant 360 CDx for comprehensive biomarker testing for patients with any solid tumor. The FDA based their approval on data from the clinical trials FLAURA and AURA3 [...]
On May 29, 2020, the Food and Drug Administration (FDA) approved the combination of Cyramza (ramucirumab) and Tarceva (erlotinib) for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having changes in EGFR called exon [...]
On May 26, 2020, the Food and Drug Administration (FDA) approved the combination of Opdivo (nivolumab), Yervoy (ipilimumab), and two cycles of platinum-doublet chemotherapy for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having [...]
On May 22, 2020, the Food and Drug Administration (FDA) approved Alunbrig (brigatinib) for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having changes in ALK. The FDA based their approval on the results [...]
By Jennifer C. King, PhD, Chief Scientific Officer I’m an optimist at heart -- to the point where my tween daughter just rolls her eyes at me whenever I tell her to have a more positive attitude. Consequently, while [...]